Continuing empagliflozin during heart failure hospitalizations
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You are currently in the hospital for heart failure.
- You are already taking an SGLT2 inhibitor (like empagliflozin) for heart failure.
- You have elevated BNP or NT-proBNP levels.
- You do not have type 1 diabetes.
- You do not have severe kidney disease or require dialysis.
- You can provide informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether empagliflozin, a blood-sugar–related medicine, can safely improve chronic low blood sodium when you are not too “dry” or have an imbalanced fluid state. It may help stabilize sodium levels and related health symptoms, but you must meet specific blood and organ-function criteria.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This trial tests whether a diabetes medicine called empagliflozin can improve the quality of life for people who have both chronic heart failure with a weak heart pump and type 2 diabetes. It compares the effects of adding empagliflozin to your current treatments.
Hear when a new Acute Decompensated Heart Failure (ADHF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.